Cognition Therapeutics, Inc.

As of June 2, 2025, the trend is mildly bearish due to daily moving averages and weekly KST showing bearish momentum, despite some underlying strength indicated by weekly and monthly MACD and a bullish monthly RSI, resulting in a cautious outlook.

Cognition Therapeutics, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, currently reporting a net profit loss of $8 million and a market cap of $17.36 million. Key metrics include a negative P/E ratio, a 0.00% dividend yield, and a debt-to-equity ratio of -1.32.

As of Jun 18, Cognition Therapeutics, Inc. has a market capitalization of 17.36 million, with net sales of 0.00 million and a net profit of -33.30 million over the last four quarters. The company reported shareholder's funds of 18.75 million and total assets of 30.23 million as of Dec 24.